180 Life Sciences Corp. ATNF
We take great care to ensure that the data presented and summarized in this overview for 180 Life Sciences Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ATNF
Top Purchases
Top Sells
About ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Insider Transactions at ATNF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2023
|
Marc Feldmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
135,377
+35.05%
|
-
|
|
Dec 15
2023
|
James N. Woody Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+27.21%
|
$0
$0.19 P/Share
|
|
Dec 15
2023
|
Marc Feldmann Director |
SELL
Open market or private sale
|
Direct |
25,000
-17.79%
|
$0
$0.19 P/Share
|
|
Sep 04
2023
|
Russell T Ray Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,455
+46.78%
|
$21,455
$1.36 P/Share
|
|
Sep 04
2023
|
Lawrence Marshall Gold Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,455
+46.44%
|
-
|
|
Sep 04
2023
|
Pamela G Marrone Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,388
+39.11%
|
-
|
|
Sep 04
2023
|
Jr. Donald A. Mc Govern Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,186
+31.3%
|
-
|
|
Jun 01
2023
|
Lawrence Steinman Director |
BUY
Open market or private purchase
|
Direct |
18,000
+27.22%
|
$18,000
$1.23 P/Share
|
|
May 31
2023
|
Jr. Donald A. Mc Govern Director |
BUY
Open market or private purchase
|
Direct |
10,000
+24.94%
|
$10,000
$1.15 P/Share
|
|
May 19
2023
|
Jr. Donald A. Mc Govern Director |
BUY
Open market or private purchase
|
Direct |
5,000
+19.92%
|
$5,000
$1.16 P/Share
|
|
May 18
2023
|
Jr. Donald A. Mc Govern Director |
BUY
Open market or private purchase
|
Direct |
10,000
+39.84%
|
$10,000
$1.05 P/Share
|
|
May 18
2023
|
Pamela G Marrone Director |
BUY
Open market or private purchase
|
Direct |
7,082
+36.22%
|
$7,082
$1.06 P/Share
|
|
May 18
2023
|
Ozan Pamir CFO |
BUY
Open market or private purchase
|
Direct |
5,162
+36.49%
|
$5,162
$1.01 P/Share
|
|
May 18
2023
|
James N. Woody Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
40,000
+48.85%
|
$40,000
$1.03 P/Share
|
|
Oct 31
2022
|
Jr. Donald A. Mc Govern Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,042
+26.12%
|
-
|
|
Oct 31
2022
|
Russell T Ray Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,702
+34.2%
|
-
|
|
Oct 31
2022
|
Pamela G Marrone Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,037
+34.74%
|
-
|
|
Oct 31
2022
|
Lawrence Marshall Gold Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,702
+31.82%
|
-
|
|
Jul 27
2022
|
Lawrence Marshall Gold Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,068
+27.13%
|
-
|
|
Jul 27
2022
|
Jr. Donald A. Mc Govern Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,340
+18.88%
|
-
|